CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, X. F.
Right arrow Articles by Hsu, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, X. F.
Right arrow Articles by Hsu, T. C.

Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 7 527-532, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients

XF Wu, MR Spitz, GL Delclos, TH Connor, Y Zhao, MJ Siciliano and TC Hsu
Department of Epidemiology, University of Texas M. D. Anderson Cancer Center 77030, USA.

In a previous study of lung cancer, we showed that bleomycin, a radiomimetic agent, induced breaks preferentially on chromosomes 4 and 5. The molecular cytogenetic study reported here, using chromosome painting and G banding, was designed to assess whether the chromatid breaks induced by bleomycin could survive as chromosome-type aberrations after treated lymphocyte populations were allowed to recover in a drug-free medium for one or two cell generations and whether the survival rates of lesions on chromosomes 4 and 5 differed in cases with lung cancer and controls. The findings from 16 cases and 14 controls showed that in samples allowed to recover for 48 h, most aberrations were of the chromosome type. The proportion of chromosome 5 abnormalities surviving as chromosome-type aberrations was significantly higher in the cells of lung cancer cases (13.4%) than in controls (4.6%; P < 0.0001). However, no significant differences in survival of chromosome 4 abnormalities were detected between cases and controls. The proportions of chromosome 5q13-q22 abnormalities were 5.3% in the cases and 0.6% in the controls (P < 0.0001). 5q13-q22 regions encompassed 38.4% of all abnormalities on chromosome 5 in the cases but only 14.5% in the controls. Therefore, the survival rate of chromosome 5 lesions (especially those at 5q13-q22) in lymphocytes might be used as a biomarker to identify populations at high risk for lung cancer.


This article has been cited by other articles:


Home page
Hum ReprodHome page
J. Lin, X. Zhang, and Y. Chen
Mutagen sensitivity as a susceptibility marker for endometriosis
Hum. Reprod., October 1, 2003; 18(10): 2052 - 2057.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. R. Spitz, Q. Wei, Q. Dong, C. I. Amos, and X. Wu
Genetic Susceptibility to Lung Cancer: The Role of DNA Damage and Repair
Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 689 - 698.
[Full Text] [PDF]


Home page
CarcinogenesisHome page
D. H. Auckley, R. E. Crowell, E. R. Heaphy, C. A. Stidley, J. F. Lechner, F. D. Gilliland, and S. A. Belinsky
Reduced DNA-dependent protein kinase activity is associated with lung cancer
Carcinogenesis, May 1, 2001; 22(5): 723 - 727.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.